HROW vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

HROW

47.7
AI Score
VS
PCRX Wins

PCRX

58.6
AI Score

Investment Advisor Scores

HROW

48score
Recommendation
HOLD

PCRX

59score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HROW PCRX Winner
Revenue 114.86M 369.77M PCRX
Net Income -44.87M 7.57M PCRX
Net Margin -39.1% 2.0% PCRX
Operating Income -33.09M 11.17M PCRX
ROE -295.2% 1.1% PCRX
ROA -10.8% 0.6% PCRX
Total Assets 416.82M 1.24B PCRX
Cash 83.89M 205.88M PCRX
Current Ratio 2.24 5.04 PCRX
Free Cash Flow -19.43M 79.08M PCRX

Relative Price Performance (Last 90 Days)

HROW 1M: -2.2% · 3M: +24.2% PCRX 1M: -4.9% · 3M: +5.1%

Current Technical Phase

HROW

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 52.7 · Price: $40.95

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.5 · Price: $24.67

Fundamentals Snapshot

Metric HROW PCRX
Market Cap
Forward P/E 15.0 6.9
Trailing P/E 67.7
Revenue (TTM)
Revenue Growth 0.1% 0.1%
Gross Margin 0.7% 0.8%
Operating Margin -0.2% 0.1%
EPS -1.00 0.36
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.